✦ LIBER ✦

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

✍ Scribed by Buske, C; Hoster, E; Dreyling, M; Eimermacher, H; Wandt, H; Metzner, B; Fuchs, R; Bittenbring, J; Woermann, B; Hohloch, K

Book ID: 109886625
Publisher: Nature Publishing Group
Year: 2008
Tongue: English
Weight: 231 KB
Volume: 23
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2008.261

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined cyclophosphamide, vincristine,

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas : Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group

✍ Christina Nickenig; Martin Dreyling; Eva Hoster; Michael Pfreundschuh; Lorenz Tr 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB 👁 2 views

## Abstract ## BACKGROUND. In patients with advanced‐stage follicular lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades. ## METHODS. The German Low‐Grade Lymphom

Treatment of Bendamustine and Prednisone

Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

✍ W. Pönisch; P. S. Mitrou; K. Merkle; M. Herold; M. Assmann; G. Wilhelm; K. Dachs 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 344 KB